Physician profile
Michael Eugene Shapiro
NPI 1043717622
$1,989.50
in general payments reported to CMS, 2019-2025
22 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $500 · 2024: $308 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,635 · Consulting Fee: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,634.50 |
| Consulting Fee | $355.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dornier Medtech America, INC | $522.27 | 2025 | Dornier Medtech |
| Medtronic, INC. | $375.92 | 2024-2025 | Nuro, Interstim |
| Teleflex LLC | $287.87 | 2023-2025 | Urolift, Barrigel |
| Genzyme Corporation | $121.54 | 2023 | |
| Tempus Ai, INC | $119.31 | 2024 | Xt Cdx |
| Progenics Pharmaceuticals, INC. | $82.23 | 2023-2025 | Pylarify |
| Coloplast Corp | $67.77 | 2023 | Titan |
| Abbvie INC. | $57.91 | 2023-2025 | Botox |
| Boston Scientific Corporation | $44.89 | 2025 | Axonics |
| Blue Earth Diagnostics | $37.18 | 2024-2025 | Posluma |
| Abc Home Medical Supply, INC. | $31.33 | 2025 | |
| Astellas Pharma US INC | $31.17 | 2025 | Xtandi |
| Merck Sharp & Dohme LLC | $30.92 | 2024-2025 | Keytruda, Welireg |
| Becton, Dickinson and Company | $29.40 | 2025 | Magic3 Intermittent Catheter |
| Olympus America INC. | $28.67 | 2025 | Itind System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $26.94 | 2025 | |
| Janssen Biotech, INC. | $17.32 | 2024 | Erleada, Akeega |
| 180 Medical, INC. | $17.07 | 2023 | Gentlecath Glide |
| Sumitomo Pharma America, INC. | $16.47 | 2023 | Orgovyx |
| Halozyme INC | $15.52 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $13.94 | 2025 | Lynparza |
| Hollister Incorporated | $13.86 | 2023 | Vapro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.